23.7 C
April 14, 2024
Let Out  News
Image default
Editor's Picks Science & Technology

Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.

“Over one million cases of cancer are diagnosed in Africa each year2. With many African communities living in rural areas or far from healthcare centres, waiting for a diagnosis is often one of the most stressful times. The BenchMark ULTRA PLUS enables pathologists to provide quick and accurate results that help inform patient treatment options, timeously.” says Alan Yates Ad-Interim General Manager South Africa & SADC markets, Roche Diagnostics.

Cancer and other abnormal cells can be characterised by biochemical markers from within the cells. By applying chemical solutions to tissue on glass slides with the BenchMark ULTRA PLUS, a healthcare professional can identify these markers to determine the presence or absence of key drivers that feed the unhealthy cells and, in many cases, the type of therapy that could be used to combat them3.

The new BenchMark ULTRA PLUS system continues the evolution of the BenchMark series, which revolutionised cancer diagnostics by fully automating processes that used to be performed manually, one slide at a time.

Lab personnel will be able to manage their activities more efficiently as a result of simplified software and streamlined productivity and quality control. These enhancements can help support the quicker delivery of test results for patients who are waiting for a diagnosis.

The new system has several innovations such as new intuitive software, remote monitoring features, an integrated touchscreen for a more optimised user experience, and a more environmentally sustainable waste system and product packaging1&4.

The BenchMark ULTRA PLUS system will be available in South Africa, Zimbabwe, Zambia, Malawi, Lesotho, Namibia and Mauritius in 2023.

About the BenchMark ULTRA PLUS system

The BenchMark ULTRA PLUS system (including hardware, software and assays) leverages the success of the current BenchMark series of IHC/ISH advanced staining platforms. It is built upon the proven technology of the BenchMark ULTRA system to deliver an enhanced lab experience. The BenchMark ULTRA PLUS system provides optimised workflow and flexible solutions, helping the anatomic pathology lab manage their activities efficiently and confidently, while selecting options that work best for their lab.

BenchMark ULTRA was the first advanced staining instrument to provide true, single-piece flow. BenchMark ULTRA PLUS pushes the envelope even further with its improved VENTANA System Software, which enhances quality control, inventory management and overall user experience due to its modern architecture1.

The BenchMark ULTRA PLUS incorporates several additional innovative features based on customer feedback, including remote monitoring with a connected device, new indicator lights, a retractable work surface, new slide drawers (that mitigate fluid ingress/egress), a new integrated touchscreen and more environmentally friendly waste segregation and degradation. Sustainable packaging uses 40% fewer raw materials and weighs less to provide a smaller carbon footprint while being transported. The system is manufactured using innovative and efficient assembly practices to ensure product quality and delivery1.

The BenchMark ULTRA PLUS system (including hardware, software and assays) leverages the success of the current BenchMark series of IHC/ISH advanced staining platforms.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.


  • The BenchMark ULTRA PLUS tissue staining system, with optimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide high-quality, time-critical results to doctors and patients1.
  • With laboratory diagnostics involved in more than two-thirds of healthcare decision making, innovative laboratory solutions that enable an accurate and timely diagnosis are crucial to successful treatment.
  • About 17 million new cases of cancer are diagnosed worldwide each year, and nearly 10 million people die from the disease.2

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.


[1] https://pim.dia.roche.com/PdfViewer/?documentId=095e517a-a9db-ec11-1591-005056a71a5d&isAttachment=False&parentId=00000000-0000-0000-0000-000000000000&is
[2] Global Cancer Facts and Figures, https://www.cancer.org/research/cancer-facts-statistics/global.html

 [3] National Library of Medicine, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319530/pdf/ cmar-12-4789.pdf

 [4] https://diagnostics.roche.com/global/en/products/instruments/benchmark-ultra-plus-ins-6476.html#productInfo

Related posts

Maracana back with May soccer fest Gala

Edwin Musaazi

It’s a curse to get wealth through corruption -Museveni

Sigmund Ainembabazi

Kampala lord Mayor Erias Lukwago advises President Museveni on how to govern Uganda

Sigmund Ainembabazi

Leave a Reply

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More